Genmab's petosemtamab-pembrolizumab combination achieves 28.2-month median survival in Phase 2 head and neck cancer trial
GMAB•Genmab reported updated Phase 2 results for petosemtamab combined with pembrolizumab in first-line recurrent or metastatic head and neck cancer, with median survival of 28.2 months.
1. Phase 2 results
Genmab reported durable responses with the combination, with responses across patient subgroups including HPV-positive and HPV-negative disease. No treatment-related deaths were reported, and all infusion-related reactions resolved.
2. Development program
The results were presented at the European Society for Medical Oncology Congress 2026 in Madrid. Genmab's petosemtamab development program includes four Phase 3 trials across head and neck cancer and colorectal cancer.
